Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$42.05 USD

42.05
4,553,145

-0.62 (-1.45%)

Updated Jul 23, 2024 12:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC

by Ahan Chakraborty

Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.

Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.

Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals

by Zacks Equity Research

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.

Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) reachead $57.17 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.

Ekta Bagri headshot

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

by Ekta Bagri

Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.

Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data

by Zacks Equity Research

Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.

The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer

by Zacks Equity Research

Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

by Kinjel Shah

The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.

Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why

by Zacks Equity Research

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.

Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $56.61, indicating a -0.09% shift from the previous trading day.

Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B

by Zacks Equity Research

Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.

Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B

by Zacks Equity Research

Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $57.85 in the latest trading session, marking a -0.33% move from the prior day.

FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease

by Zacks Equity Research

The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

by Zacks Equity Research

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $59.16 in the latest trading session, marking a +0.44% move from the prior day.

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

by Zacks Equity Research

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $58.58 in the latest trading session, marking a -0.76% move from the prior day.

Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates

by Zacks Equity Research

Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

by Zacks Equity Research

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

The Zacks Analyst Blog Highlights Mastercard, SAP, Texas Instruments, Bristol-Myers Squibb and AT&T

by Zacks Equity Research

Mastercard, SAP, Texas Instruments, Bristol-Myers Squibb and AT&T are included in this Analyst Blog.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $60.24 in the latest trading session, marking a -0.94% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for Mastercard, SAP & Texas Instruments

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), SAP SE (SAP) and Texas Instruments Incorporated (TXN).